# US 2021/0087141 A1 · Compounds having s1p5 receptor agonistic activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0087141 A1
- Document ID: US20210087141A1
- Status: Published application
- Kind: A1
- Application number: 16/970,865
- Filed: 2019-02-21
- Published: 2021-03-25
- Earliest claimed: 2018-02-22
- Assignees: Ono Pharmaceutical Co., Ltd.
- Applicants: Ono Pharmaceutical Co., Ltd.
- Inventors: Toshihide WATANABE; Kensuke KUSUMI; Satomi IMAIDE; Toshimitsu ENDO; Takaki KOMIYA; Naomi TSUBURAYA
- Web page: https://patentgrep.com/patent/US20210087141A1

## CPC

- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07C 49/252: containing six-membered aromatic rings and other rings
- C07C 49/577: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

## Claims

### Claim 1

A compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof:
wherein
L is a branched or linear chain group composed of atoms selected from a carbon atom, an oxygen atom, a nitrogen atom, and a sulfur atom, in which the number of atoms in the main chain thereof is 3 to 8, and the chain group may contain 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom,
provided that a carbon atom in L may be substituted with 1 to 13 halogen atoms,
Y represents
wherein each group is bound to Z through a bond represented by an arrow,
A represents a C3-7 cycloalkylene group which may be substituted or a C1-4 alkylene group which may be substituted,
R1 represents a C1-4 alkyl group, a C3-6 cycloalkyl group which may be substituted with a halogen, a C1-4 alkoxy group which may be substituted with a halogen, a C1-4 haloalkyl group, a halogen atom, or a hydroxy group,
R2 represents a C1-4 alkyl group, a C1-4 alkoxy group which may be substituted with a halogen, a C1-4 haloalkyl group, a halogen atom, or a hydroxy group,
R3, R4, and R5 each independently represent a hydrogen atom, a C1-4 alkyl group, a C3-6 cycloalkyl group which may be substituted with a halogen, or a C1-4 haloalkyl group,
Z represents (1) a carboxyl group which may be substituted with one C1-8 alkyl group, (2) a hydroxy group which may be substituted with one C1-8 alkyl group, (3) a hydroxamic acid group which may be substituted with one to two C1-8 alkyl groups, (4) a sulfonic acid group which may be substituted with one C1-8 alkyl group, (5) a boronic acid group which may be substituted with one to two C1-8 alkyl groups, (6) a carbamoyl group which may be substituted with (i) one to two C1-8 alkyl groups or (ii) one to two sulfonyl groups which may be substituted with a C1-4 alkyl group, (7) a sulfamoyl group which may be substituted with (i) one to two C1-8 alkyl groups or (ii) one to two C2-8 acyl groups, (8) a sulfoximine group which may be substituted with one to two C1-8 alkyl groups, or (9) a tetrazolyl group,
ring 2 represents a 3- to 7-membered nitrogen-containing heterocycle,
m represents an integer of 0 to 6,
n represents an integer of 0 to 5,
when m is 2 or more, a plurality of R1s may be the same or different, and
when n is 2 or more, a plurality of R2s may be the same or different,
provided that each hydrogen atom may be a deuterium atom or a tritium atom.

### Claim 2 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is a compound represented by the general formula (V-1):
wherein all the symbols represent the same meanings as described in claim 1,
provided that each hydrogen atom may be a deuterium atom or a tritium atom.

### Claim 3 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein
L is (1) —O—(C2-7 alkyl), (2) —O—(C2-7 alkenyl), (3) —O—(C2-7 alkynyl), (4) —O—(C1-5 alkylene)-OCH3, (5) —O—(C1-4 alkylene)-OCH2CH3, (6) —CH2O—(C1-6 alkyl), (7) —CH2O—(C2-6 alkenyl), (8) —CH2O—(C2-6 alkynyl), (9) —CH2CH2O—(C1-5 alkyl), (10) —CH2CH2O—(C2-5 alkenyl), (11) —CH2CH2O—(C2-5 alkynyl), (12) —S—(C2-7 alkyl), (13) —S—(C2-7 alkenyl), (14) —S—(C2-7 alkynyl), (15) —NR6—(C2-7 alkyl), (16) —NR6—(C2-7 alkenyl), (17) —NR6—(C2-7 alkynyl), (18) a C3-8 alkyl group, (19) a C3-8 alkenyl group, or (20) a C3-8 alkynyl group, and
R6 represents a hydrogen atom or a C1-4 alkyl group,
provided that a carbon atom in each group may be substituted with 1 to 13 halogen atoms.

### Claim 4 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein L is a branched or linear chain group in which the number of atoms in the main chain is 4 to 7.

### Claim 5 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein
L is (1) —O—(C3-6 alkyl), (2) —O—(C3-6 alkenyl), (3) —O—(C3-6 alkynyl), (4) —O—(C1-4 alkylene)-OCH3, (5) —O—(C1-3 alkylene)-OCH2CH3, (6) —CH2O—(C2-5 alkyl), (7) —CH2O—(C2-5 alkenyl), (8) —CH2O—(C2-5 alkynyl), (9) —CH2CH2O—(C1-4 alkyl), (10) —CH2CH2O—(C2-4 alkenyl), (11) —CH2CH2O—(C2-4 alkynyl), (12) —S—(C3-6 alkyl), (13) —S—(C3-6 alkenyl), (14) —S—(C3-6 alkynyl), (15) —NR6—(C3-6 alkyl), (16) —NR6—(C3-6 alkenyl), (17) —NR6—(C3-6 alkynyl), (18) a C4-7 alkyl group, (19) a C4-7 alkenyl group, or (20) a C4-7 alkynyl group, and
R6 represents a hydrogen atom or a C1-4 alkyl group,
provided that a carbon atom in each group may be substituted with 1 to 13 halogen atoms.

### Claim 6 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein ring 2 is a 3- to 7-membered nitrogen-containing saturated heterocycle.

### Claim 7 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is a compound represented by the general formula (V-2):
wherein
L1 is a branched or linear chain group composed of atoms selected from a carbon atom, an oxygen atom, a nitrogen atom, and a sulfur atom, in which the number of atoms in the main chain thereof is 4 to 7, and the chain group may contain 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom,
provided that a carbon atom in L1 may be substituted with 1 to 13 halogen atoms,
ring 2-1 represents a 3- to 7-membered nitrogen-containing saturated heterocycle,
m-1 represents an integer of 0 to 2,
n-1 represents an integer of 0 to 2,
when m-1 is 2, a plurality of R1s may be the same or different,
when n-1 is 2, a plurality of R2s may be the same or different, and
the other symbols represent the same meanings as describe in claim 1,
provided that each hydrogen atom may be a deuterium atom or a tritium atom.

### Claim 8 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Z is a carboxyl group which may be substituted with one C1-8 alkyl group, or a tetrazolyl group.

### Claim 9 (depends on 7)

The compound or a pharmaceutically acceptable salt thereof according to claim 7, wherein
L1 is (1) —O—(C3-6 alkyl), (2) —O—(C3-6 alkenyl), (3) —O—(C3-6 alkynyl), (4) —O—(C1-4 alkylene)-OCH3, (5) —O—(C1-3 alkylene)-OCH2CH3, (6) —CH2O—(C2-5 alkyl), (7) —CH2O—(C2-5 alkenyl), (8) —CH2O—(C2-5 alkynyl), (9) —CH2CH2O—(C1-4 alkyl), (10) —CH2CH2O—(C2-4 alkenyl), (11) —CH2CH2O—(C2-4 alkynyl), (12) —S—(C3-6 alkyl), (13) —S—(C3-6 alkenyl), (14) —S—(C3-6 alkynyl), (15) —NR6—(C3-6 alkyl), (16) —NR6—(C3-6 alkenyl), (17) —NR6—(C3-6 alkynyl), (18) a C4-7 alkyl group, (19) a C4-7 alkenyl group, or (20) a C4-7 alkynyl group, and
R6 represents a hydrogen atom or a C1-4 alkyl group,
provided that a carbon atom in each group may be substituted with 1 to 13 halogen atoms.

### Claim 10 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is a C1-4 alkyl group or a halogen atom.

### Claim 11 (depends on 7)

The compound or a pharmaceutically acceptable salt thereof according to claim 7, wherein ring 2-1 is azetidine, pyrrolidine, piperidine, or perhydroazepine.

### Claim 12 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is (1) 1-[((3R)-6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl)methyl]azetidine-3-carboxylic acid, (2) 1-[((3S)-6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl)methyl]azetidine-3-carboxylic acid, (3) 1-[((3S)-3-methyl-6-pentoxy-3,4-dihydronaphthalen-2-yl)methyl]azetidine-3-carboxylic acid, (4) 1-[[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid, (5) 3-fluoro-1-[[(3S)-3-methyl-6-(3,4,4-trifluorobut-3-enoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid, (6) 1-[[(3S)-3-methyl-6-(1,1,2,2,3,3,4,4,4-nonadeuteriobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid, (7) (3R)-1-[[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]pyrrolidine-3-carboxylic acid, (8) 1-[[(3S)-3-methyl-6-((R)-3,3,3-trifluoro-2-methylpropoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid, (9) 1-[[(3S)-3-methyl-6-((S)-3,3,3-trifluoro-2-methylpropoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid, (10) 3-fluoro-1-[[(3S)-3-methyl-6-[(E)-4,4,4-trifluorobut-2-enoxy]-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid, (11) 3-fluoro-1-{[(3S)-3-methyl-6-(3,3,3-trifluoropropoxy)-3,4-dihydro-2-naphthalenyl]methyl}-3-azetidinecarboxylic acid, (12) cis-3-({1-[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydro-2-naphthalenyl]ethyl}amino)cyclobutanecarboxylic acid, or (13) 1-{[(3S)-3-methyl-6-(propoxymethyl)-3,4-dihydro-2-naphthalenyl]methyl}-3-azetidinecarboxylic acid.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof according to claim 1.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, which is an S1P5 agonist.

### Claim 15 (depends on 13)

The pharmaceutical composition according to claim 13, which is a prophylactic and/or therapeutic agent for an S1P5-mediated disease.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, wherein the S1P5-mediated disease is a neurodegenerative disease, an autoimmune disease, an infectious disease, or cancer.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, wherein the S1P5-mediated disease is a neurodegenerative disease, and the neurodegenerative disease is schizophrenia, Binswanger's disease, multiple sclerosis, neuromyelitis optica, Alzheimer-type dementia, cognitive impairment, amyotrophic lateral sclerosis, spinocerebellar degeneration, multiple system atrophy, Parkinson's disease, or Lewy body dementia.

### Claim 18 (depends on 1)

A method for preventing and/or treating an S1P5-mediated disease, comprising administering an effective amount of the compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof according to claim 1 to a mammal.

### Claim 19 (depends on 1)

The compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof according to claim 1, adapted for use in preventing and/or treating an S1P5-mediated disease.

### Claim 20 (depends on 1)

A method for manufacturing a prophylactic and/or therapeutic agent for an S1P5-mediated disease, comprising providing, as part of the agent, the compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof according to claim 1.
